Reuters Market Eye - Shares in Sun Pharmaceutical Industries(SUN.NS) gain 1.8 percent after Credit Suisse said the drug maker's subsidiary Taro Pharmaceutical Industries (TARO.N) has pushed through price increases in three products last week, citing industry checks.
Credit Suisse estimates those three drugs account for 35 percent of Taro U.S. sales.
The price increases raise sustainable sales estimates for Taro to $680 million versus $640 million earlier for FY 2015, the investment bank adds.
Credit Suisse maintains its "outperform" rating on the stock and raises its target price to 900 rupees from 840 rupees, in part by factoring higher sales estimates for Taro.
(Reporting by Abhishek Vishnoi)
Trending On Reuters
State Bank of India, the nation's top lender by assets, reported a better-than-expected 23 percent rise in quarterly profit on Friday and said its bad loan ratio declined sharply, sending its shares up by more than 5 percent. Full Article | Full Coverage
Gold demand slows as China eyes equities; lack of weddings in India weighs Full Article